Patents Issued in May 10, 2018
  • METHOD OF INHIBITING MUTANT C-KIT
    Publication number: 20180125839
    Abstract: The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention: or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 4, 2018
    Publication date: May 10, 2018
    Inventor: Vinay K. Jain
  • TREATMENT OF PRURIGO NODULARIS
    Publication number: 20180125840
    Abstract: The present invention relates to methods for treating prurigo nodularis with anti-pruritic compositions, wherein the method provides a therapeutic effect in a patient.
    Type: Application
    Filed: October 25, 2017
    Publication date: May 10, 2018
    Inventors: Thomas Sciascia, Jennifer L. Good, Amale Hawi
  • KETOCONAZOLE ENANTIOMER IN HUMANS
    Publication number: 20180125841
    Abstract: Treatment of patients with the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 10, 2018
    Inventor: Timothy Andrew Stewart
  • Ergoloid for Cancer
    Publication number: 20180125842
    Abstract: A drug developed to treat dementia which has been abandoned by its manufacturer, Novartis, is repurposed to enhance the treatment of cancer. The drug, Ergoloid, contains four gamma secretase inhibitors that produce the same benefit as single gamma secretase inhibitors that are in clinical trials to enhance the treatment of cancer. The method of this invention is to administer Ergoluid 1 mg three times a day by mouth. This enhancement results in better outcomes with lower cost and better quality of life.
    Type: Application
    Filed: November 10, 2016
    Publication date: May 10, 2018
    Inventors: Ronald Blair Hartman, Renee Marie Hartman
  • Method Of Treating Metabolic Disorders And Depression With Dopamine Receptor Agonists
    Publication number: 20180125843
    Abstract: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 10, 2018
    Inventor: Anthony H. Cincotta
  • TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS
    Publication number: 20180125844
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Application
    Filed: August 9, 2017
    Publication date: May 10, 2018
    Applicant: CELGENE CORPORATION
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
    Publication number: 20180125845
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Application
    Filed: August 23, 2017
    Publication date: May 10, 2018
    Inventors: Andrew G. Reaume, Michael S. Saporito
  • Targeted Therapies for Cancer
    Publication number: 20180125846
    Abstract: Methods of treating, and for selecting a chemotherapy regimen for treatment of cancer in a patient (FIG. 9). For example, a patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFII and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFII is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
    Type: Application
    Filed: August 1, 2017
    Publication date: May 10, 2018
    Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Mitesh Jivraj Borad, David Craig, John Carpten
  • METHODS FOR TREATMENT OF RETINAL DISEASE BY PHOTORECEPTOR GENE EXPRESSION MODULATION
    Publication number: 20180125847
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Application
    Filed: March 28, 2016
    Publication date: May 10, 2018
    Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
    Publication number: 20180125848
    Abstract: The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.
    Type: Application
    Filed: November 2, 2017
    Publication date: May 10, 2018
    Inventor: Gary A. Flynn
  • PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS
    Publication number: 20180125849
    Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 10, 2018
    Inventors: Graham Charles Bloomfield, Ian Bruce, Brian Cox, Lee Edwards, Judy Fox Hayler, Catherine Howsham
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20180125850
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).
    Type: Application
    Filed: January 8, 2018
    Publication date: May 10, 2018
    Inventor: Samuel V. Agresta
  • METHODS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20180125851
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: July 7, 2017
    Publication date: May 10, 2018
    Inventors: Laxminarayan Bhat, Marc Cantillon, Ellen M. Wallis, Seema Rani Bhat
  • COMPOSITIONS AND METHODS FOR TREATMENT OF GLIOMA
    Publication number: 20180125852
    Abstract: In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a CSF-IR inhibitor together with one or more additional active agents such as IGF-IR inhibitors, PI3K inhibitors, IL4 inhibitors, NFAT inhibitors, and/or Stat6 inhibitors. In certain embodiments the present invention provides pharmaceutical compositions comprising a CSF-IR inhibitor together with one or more of such additional active agents.
    Type: Application
    Filed: May 9, 2016
    Publication date: May 10, 2018
    Inventors: Daniela Francis Quail, Johanna Alexandra Joyce, Robert Lyle Bowman
  • OXAZINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL AMYLOID ANGIOPATHY
    Publication number: 20180125853
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.
    Type: Application
    Filed: October 11, 2017
    Publication date: May 10, 2018
    Inventors: Cristina LOPEZ-LOPEZ, Ulf NEUMANN, Derya SHIMSHEK
  • THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20180125854
    Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Application
    Filed: January 3, 2018
    Publication date: May 10, 2018
    Applicant: PFIZER INC.
    Inventors: Shubha Bagrodia, Jennifer Lafontaine, Zach Lovatt, Eyoung Shin, Young Ho Song, Greg Troiano, Hong Wang
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20180125855
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: November 7, 2017
    Publication date: May 10, 2018
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • USE OF GLUCOCORTICOID RECEPTOR ANTAGONIST AND SOMATOSTATIN ANALOGUES TO TREAT ACTH-SECRETING TUMORS
    Publication number: 20180125856
    Abstract: Methods, compositions, and pharmaceutical formulations are provided for treatment of ACTH secreting tumors.
    Type: Application
    Filed: June 19, 2017
    Publication date: May 10, 2018
    Inventors: Andreas G. Moraitis, Joseph K. Belanoff
  • HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS
    Publication number: 20180125857
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Application
    Filed: August 7, 2017
    Publication date: May 10, 2018
    Applicant: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • BIOAVAILABLE SOLID STATE (17- β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
    Publication number: 20180125858
    Abstract: Disclosed are bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-?)-Hydroxy-4-Androsten-3-one.
    Type: Application
    Filed: August 8, 2017
    Publication date: May 10, 2018
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank
  • Methods for Inhibiting the Development of Huntington's Disease
    Publication number: 20180125859
    Abstract: This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof.
    Type: Application
    Filed: January 4, 2018
    Publication date: May 10, 2018
    Inventor: James A. Carnazza
  • Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
    Publication number: 20180125860
    Abstract: Compositions and methods for the delivery of progestin hormones that have binding affinity to the Sex Hormone Binding Globulin (SHBG) are disclosed. The compositions combine such progestins with non-progestin SHBG ligands to displace at least part of the progestin from SHBG in the blood plasma, thereby increasing its bioavailability. Also disclosed are methods to modulate progestin and estrogen levels in the blood through the use of SHBG binding and displacement, to optimize the effectiveness of formulations for contraception and minimize the side effects and adverse events.
    Type: Application
    Filed: May 18, 2016
    Publication date: May 10, 2018
    Applicant: Agile Therapeutics, Inc.
    Inventors: Agis Kydonieus, Michael E. Kafrissen, Katie Macfarlane
  • OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES
    Publication number: 20180125861
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 10, 2018
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • TREATMENT FOR HEPATIC FIBROSIS
    Publication number: 20180125862
    Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.
    Type: Application
    Filed: October 20, 2017
    Publication date: May 10, 2018
    Applicant: Galmed Research and Development Ltd.
    Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
  • ABIRATERONE ACETATE LIPID FORMULATIONS
    Publication number: 20180125863
    Abstract: Abiraterone acetate lipid formulations.
    Type: Application
    Filed: March 25, 2016
    Publication date: May 10, 2018
    Inventors: Hywel Williams, Prashant Agarwal, Eduardo Jule
  • A METHOD FOR SCREENING REGULATOR OF MITOCHONDRIAL FISSION
    Publication number: 20180125864
    Abstract: The present invention is directed to a method for screening a regulator of mitochondrial fission using a cell treated to a protopanaxadiol (PPD)-type ginsenoside compound, a composition therefor, and a kit comprising the composition. As the use of the method for screening the regulator of mitochondrial fission of the present invention enables effective discovery of a formulation capable of preventing, improving, or treating a mitochondria-related disease, the method will be widely used for the development of a therapeutic agent for the mitochondria-related disease.
    Type: Application
    Filed: July 2, 2015
    Publication date: May 10, 2018
    Inventors: Chul Hee Choi, Eun Soo Kim, Kyung Sun Choi, Seung Wook Ryu, Jin Gang Hou
  • WITHAFERIN COMPOSITIONS FOR PREVENTION OF AGING
    Publication number: 20180125865
    Abstract: The present invention provides gero-protective pharmaceutical compositions and methods, the compositions being adapted to enhance at least one of cell survival and cell metabolism in a mammalian subject, the pharmaceutical compositions include at least two of Withaferin a or its structural analogs, coumestrol, ginsenoside, quinidine, silymarin, licochalcone a, lipoic acid and apigenin, in a pharmaceutically effective amount.
    Type: Application
    Filed: September 28, 2017
    Publication date: May 10, 2018
    Inventors: Aleksandrs Zavoronkovs, Alexander Aliper, Polina Mamoshina, Artem Artemov, Ivan Ozerov
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20180125866
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: October 10, 2017
    Publication date: May 10, 2018
    Inventor: Xiangping QIAN
  • COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS
    Publication number: 20180125867
    Abstract: The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 10, 2018
    Inventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, EMMANUEL VIAL, MICKAEL GUEDJ
  • CONNECTIVE TISSUE MONITORING, COMPOSITIONS FOR CONNECTIVE TISSUE TREATMENT AND METHODS FOR TREATING CONNECTIVE TISSUE
    Publication number: 20180125868
    Abstract: A method for treating a non-hemorrhoidal tendon injury in a performance animal in need thereof includes administering to the animal a composition comprising a pro-inflammatory cytokine inhibitor, an antioxidant or catechin, and an anti-inflammatory to thereby treat the non-hemorrhoidal tendon injury in the performance animal.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 10, 2018
    Inventor: John Daffy
  • BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE
    Publication number: 20180125869
    Abstract: The present invention provides for methods and compositions for treating and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 10, 2018
    Inventors: KENNETH W. LYLES, CATHLEEN S. COLON-EMERIC, CHRISTOPHER M. O'CONNOR, RICHARD S. STACK, COLLEEN STACK
  • COMPOSITIONS, METHODS OF TREATMENT AND DIAGNOSTICS FOR TREATMENT OF HEPATIC STEATOSIS ALONE OR IN COMBINATION WITH A HEPATITIS C VIRUS INFECTION
    Publication number: 20180125870
    Abstract: The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
    Type: Application
    Filed: June 15, 2017
    Publication date: May 10, 2018
    Inventors: Joseph M. Fayad, Jerome Schentag
  • Targeting NAD+ to Treat Chemotherapy and Radiotherapy Induced Cognitive Impairment, Neuropathies and Inactivity
    Publication number: 20180125871
    Abstract: Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive performance, in a subject in need thereof are disclosed. The disclosed methods include the step of administering to the subject an effective amount of an agent that increases the level of NAD+ in the subject.
    Type: Application
    Filed: April 28, 2016
    Publication date: May 10, 2018
    Inventors: Lindsay Wu, David A. Sinclair
  • FIXED-DOSE PHARMACEUTICAL COMPOSITION COMPRISING RIFABUTIN, CLARITHROMYCIN, AND CLOFAZIMINE
    Publication number: 20180125872
    Abstract: Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.
    Type: Application
    Filed: January 2, 2018
    Publication date: May 10, 2018
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • ANALOGUES OF ETOPOSIDE FOR THE TREATMENT OF TUMOURS
    Publication number: 20180125873
    Abstract: Compounds for treatment of a patient having a tumour that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula: wherein X is O, NH and S, wherein n is 0, 1 or 2, wherein R1 and R2 are H, methyl or ethyl, or together form a group CR3R4, and wherein R3 and R4 are H, methyl or ethyl.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 10, 2018
    Inventor: Nalan UTKU
  • Compositions and Methods to Accelerate Resolution of Acute Lung Inflammation
    Publication number: 20180125874
    Abstract: The present invention provides methods and compositions for treatment of acute inflammatory diseases or disorders and/or for treatment of lung injury. Certain exemplary methods involve administering an IL-4 polypeptide or fragment thereof possessing cytokine activity or an IL-4 agonist systemically to a subject having an inflammatory disease or disorder and/or a lung injury. Other exemplary methods involve administering an inhibitor of DNA methylation systemically to a subject and/or administering an inhibitor of DNA methylation to a cell population comprising T cells (e.g., Treg cells) for introduction/re-introduction to a subject having an inflammatory disease or disorder and/or a lung injury. Compositions and cells for use in such methods are also provided.
    Type: Application
    Filed: January 8, 2016
    Publication date: May 10, 2018
    Inventors: Franco D'Alessio, Benjamin David Singer, Landon King, Neil Raj Aggarwal
  • SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS
    Publication number: 20180125875
    Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2?-deoxyuridine (fdU or foUdR) or a 5-formyl-2?-deoxyuridine derivative, optionally in combination with 5-hydroxy-2?-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2?-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2?-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.
    Type: Application
    Filed: March 17, 2015
    Publication date: May 10, 2018
    Inventors: Yoshihiro Matsumoto, Alan Edward Tomkinson, Hiroshi Ide
  • Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
    Publication number: 20180125876
    Abstract: The present invention relates to methods and pharmaceutical composition for modulation polarization and activation of macrophages. In particular, the present invention relates to methods for modulating macrophage M1/M2 polarization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of P2Y2 receptor agonists or antagonists.
    Type: Application
    Filed: May 20, 2016
    Publication date: May 10, 2018
    Inventors: Jean-Luc Perfettini, Audrey Paoletti, Marie-Lise Gougeon, Guido Kroemer, Mauro Piacentini
  • IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
    Publication number: 20180125877
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: September 15, 2017
    Publication date: May 10, 2018
    Inventors: Sudhir AGRAWAL, Daqing JIANG, Wayne JIANG
  • CONTINUOUSLY EXPRESSED THERAPEUTIC RNAS FOR TARGETED PROTEIN BINDING AND METHODS FOR THEIR USE
    Publication number: 20180125878
    Abstract: An RNA composition comprising an RNA aptamer and an shRNA molecule and/or an miRNA molecule are provided. The RNA composition may include an aptamer component that binds an enzymatic protein within a target cell and an shRNA and/or an miRNA component that facilitates trafficking of the aptamer within the target cell, such as, trafficking from the nucleus into the cytoplasm. The RNA aptamer and the shRNA and/or the miRNA component of the composition can be a fusion or independent molecules.
    Type: Application
    Filed: November 1, 2017
    Publication date: May 10, 2018
    Inventors: Ka Ming PANG, John J. ROSSI
  • Use of Polysaccharide for Treating ST-Elevation Myocardial Infarction and Diseases of the Digestion System
    Publication number: 20180125879
    Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycelium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.
    Type: Application
    Filed: November 7, 2017
    Publication date: May 10, 2018
    Inventors: Peter Sugita, Wiwiek Widyastuti Budiliantono, Aurelia Maxine Sugita
  • COMPOSITION FOR TREATING TISSUE LESIONS
    Publication number: 20180125880
    Abstract: Some embodiments are directed to a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, to be used as a drug for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to a pharmaceutical kit which includes a biocompatible polymer in association with a eukaryotic cell for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to the use of a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, for manufacturing a drug for the treatment of tissue lesions. Some other embodiments can be used in particular in the veterinary and pharmaceutical fields.
    Type: Application
    Filed: May 26, 2016
    Publication date: May 10, 2018
    Inventor: Denis BARRITAULT
  • LINEAR POLYOL STABILIZED POLYFLUOROACRYLATE COMPOSITIONS
    Publication number: 20180125881
    Abstract: The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 10, 2018
    Inventors: Detlef Albrecht, Michael Burdick, Han-Ting Chang, Dominique Charmot, Ramakrishnan Chidambaram, Eric Connor, Sherin Halfon, I-Zu Huang, Mingjun Liu, Jonathan Mills, Werner Strüver
  • Compositions And Methods For Treating Diseases Or Disorders Using Extended Release Nitric Oxide Releasing Solutions
    Publication number: 20180125882
    Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.
    Type: Application
    Filed: August 13, 2017
    Publication date: May 10, 2018
    Inventors: Alex Stenzler, Christopher C. Miller, Gilly Regev-Shoshani
  • INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES
    Publication number: 20180125883
    Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.
    Type: Application
    Filed: September 20, 2017
    Publication date: May 10, 2018
    Inventors: Yossef Av-Gay, Christopher C. Miller, David Greenberg
  • MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA
    Publication number: 20180125884
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 10, 2018
    Inventors: Donald Jeffrey KEYSER, Alvaro F. GUILLEM
  • COMPOSITIONS COMPRISING CINNAMALDEHYDE AND ZINC AND METHODS OF USING SUCH COMPOSITIONS
    Publication number: 20180125885
    Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The cinnamaldehyde is supplemented by zinc, and the combination can be effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. The composition can improve one or more of insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood or memory.
    Type: Application
    Filed: May 24, 2016
    Publication date: May 10, 2018
    Inventors: Susana Camacho, Stephanie Michling Gonzalez, Lucas Actis Goretta, Jenny Meylan Merlini, Johannes Le Coutre
  • HIGH-PERFORMANCE ADSORBENTS BASED ON ACTIVATED CARBON HAVING HIGH MESO- AND MACROPOROSITY
    Publication number: 20180125886
    Abstract: The invention concerns high-performance adsorbents based on activated carbon of high meso- and macroporosity which are present in the form of discrete grains of activated carbon, wherein: at least 55% of the total pore volume of the high-performance adsorbents are formed by pores (i.e. meso- and macropores) having pore diameters of more than 20 ?, the high-performance adsorbents have a measure of central tendency pore diameter of more than 25 ?, and the high-performance adsorbents have a BET surface area of at least 1250 m2/g. These high-performance adsorbents are obtainable by a novel process comprising specific two-stage activation, and have, in addition to the aforementioned properties, an excellent abrasion and bursting resistance, so that they are useful for a multiplicity of different applications.
    Type: Application
    Filed: January 4, 2018
    Publication date: May 10, 2018
    Applicant: Blücher GmbH
    Inventors: Bertram Böhringer, Sven Fichtner, Jann-Michael Giebelhausen
  • ANTI-INFLAMMATORY AGENTS
    Publication number: 20180125887
    Abstract: This invention concerns anti-inflammatory agents and methods for treating inflammatory disorders. Also disclosed are methods for identifying or evaluating anti-inflammatory agents or compositions.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 10, 2018
    Inventors: Jeffrey Ravetch, Robert Anthony, Toshihiko Kobayashi, Fredrik Wermeling
  • Methods and Compositions High Scale Therapeutic Production of Memory NK Cells
    Publication number: 20180125888
    Abstract: Disclosed are compositions and methods relating to the expansion of memory NK cells.
    Type: Application
    Filed: November 8, 2016
    Publication date: May 10, 2018
    Inventors: Alicja J. Copik, Robert Y. Igarashi, Jeremiah L. Oyer, Deborah Altomare